The U.S. Food and Drug Administration has made changes to the labels for fluoroquinolone antibacterial drugs administered by mouth or injection to address potential serious safety issues. The revised “boxed warning,” the agency’s strongest warning, notes that the drugs are “associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system” that can occur together. “Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) because the risks outweigh the benefits in these patients,” the agency states. For more, see the FDA Safety Announcement.

Headline
The Centers for Medicare & Medicaid Services Nov. 13 announced it will delay enforcement of its Medicaid community engagement requirements that are set for…
Headline
The Centers for Medicare & Medicaid Services Nov. 12 announced a six-month extension to its nationwide moratoria preventing Medicare enrollment of new home…
Headline
The AHA Nov. 13 released “Interoperability and Prior Authorization: The American Hospital Association’s 2027 Guide to Electronic Prior Authorization Go-live…
Headline
Pennsylvania has recorded its seventh measles-associated death this year as a statewide outbreak of the virus continues, according to an update Nov. 13 by the…
Headline
Registration is now open for the AHA’s 2027 Healthier Together Conference, which will be held May 4-6 in Anaheim, Calif. Join healthcare leaders from across…
Headline
Beginning in 2027, the annual Hospitals Against Violence #HAVhope Day will be observed in April, rather than June, to align with Workplace Violence Prevention…